Occurrence_of_neoplasia_in_patients_with_rheumatoid_arthritis_enrolled_in_a_DMARD_Registry._Rheumatoid_Arthritis_Azathioprine_Registry_Steering_Committee._The_Rheumatoid_Arthritis_Azathioprine_Registry_(RAAR)_was_established_in_1982_to_examine_the_safety_of_azathioprine_(AZA)_and_other_disease_modifying_agents_(DMARD)_in_the_treatment_of_RA._In_yearly_followup_over_the_past_7_years,_20_malignant_conditions_have_been_reported_in_530_DMARD_treated_adult_patients_with_RA._Incidence_density_ratios_(IDR)_and_standardized_morbidity_ratios_(SMR)_were_calculated_to_assess_cancer_risk._For_all_cancers_the_SMR_was_1.52_(95%_CI_0.90-2.60)._For_men_the_SMR_was_1.71_(95%_CI_0.84-3.52);_for_women_the_SMR_was_1.52_(95%_CI_0.89-2.60)._Adjusted_for_age,_the_IDR_was_highest_in_the_70-79-year-old_study_population_(3.41)._The_age_and_sex_adjusted_SMR_for_lymphoproliferative_disorders_and_myeloma_was_8.05_(95%_CI_3.30-20.81)._The_SMR_for_lung_cancer_(n_=_6)_was_also_increased_(3.37;_95%_CI_1.58-7.34)._Compared_with_the_general_population,_patients_with_RA_requiring_DMARD_therapy_may_be_at_increased_risk_of_malignancy,_particularly_lymphoproliferative_disorders._The_RAAR_is_an_important_prospective_technique_which_will_ultimately_permit_assessment_of_neoplasia_risk_by_type_and_duration_of_DMARD_therapy.